DADC
VRNA

D.A. Davidson & Co’s Verona Pharma VRNA Stock Holding History

D.A. Davidson & Co’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-33,400
Closed -$664K – 1464
2023
Q4 		$664K Buy
33,400
+900
+3% +$13.3K 0.01% 843
2023
Q3 		$530K Hold
32,500
– – 0.01% 882
2023
Q2 		$687K Hold
32,500
– – 0.01% 820
2023
Q1 		$653K Sell
32,500
-1,500
-4% -$32.4K 0.01% 814
2022
Q4 		$888K Sell
34,000
-6,000
-15% -$79.9K 0.01% 659
2022
Q3 		$409K Sell
40,000
-4,500
-10% -$37.9K 0.01% 886
2022
Q2 		$186K Sell
44,500
-3,500
-7% -$15K ﹤0.01% 1174
2022
Q1 		$240K Hold
48,000
– – ﹤0.01% 1143
2021
Q4 		$323K Buy
48,000
+8,000
+20% +$40.9K ﹤0.01% 1033
2021
Q3 		$219K Sell
40,000
-1,900
-5% -$11.1K ﹤0.01% 1127
2021
Q2 		$274K Hold
41,900
– – ﹤0.01% 1029
2021
Q1 		$350K Sell
41,900
-57,051
-58% -$473K ﹤0.01% 911
2020
Q4 		$693K Buy
98,951
+11,566
+13% +$78.1K 0.01% 607
2020
Q3 		$545K Sell
87,385
-29,425
-25% -$203K 0.01% 589
2020
Q2 		$547K Buy
116,810
+30,080
+35% +$139K 0.01% 568
2020
Q1 		$357K Buy
+86,730
New +$476K 0.01% 675

Other funds holding VRNA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

D.A. Davidson & Co's VRNA Position: Q1 2024 in Review

D.A. Davidson & Co sold out of Verona Pharma (VRNA) in Q1 2024, closing a stake of 33,400 shares — an estimated $664K sold.

D.A. Davidson & Co first reported a position in VRNA in Q1 2020 and held it in 16 quarters. The position peaked at $888K in Q4 2022. 113 funds tracked by Wall St. Rank hold VRNA as of Q1 2024.

  • D.A. Davidson & Co reported no remaining Verona Pharma position as of Q1 2024 after selling out during the quarter.
  • D.A. Davidson & Co sold 33,400 Verona Pharma shares in Q1 2024, an estimated $664K.
  • D.A. Davidson & Co first reported a position in Verona Pharma in Q1 2020 and held it in 16 quarters.
  • D.A. Davidson & Co's Verona Pharma position peaked at $888K in Q4 2022.
  • 113 funds tracked by Wall St. Rank held Verona Pharma as of Q1 2024.

Based on D.A. Davidson & Co's 13F filing for Q1 2024, filed 13 May 2024.